Switch to:
Also traded in: Canada, Germany
» Details

Insider Trades

Latest Guru Trades with IPCI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 3741
Compare:AMEX:NAVB, AMEX:PIP, NAS:KALV, NAS:GTXI, NAS:BLRX, NAS:AGLE, NAS:CBAY, OTCPK:IMMG, OTCPK:CNNRF, NAS:SBPH, NAS:PULM, NAS:BUR, NAS:BCLI, OTCPK:CWBR, NAS:CAPR, OTCPK:TBQBF, NAS:TTNP, NAS:AXSM, OTCPK:NEWG, NAS:CASI » details
Traded in other countries:I.Canada, I4A.Germany,
IntelliPharmaCeutics International Inc is a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs.

IntelliPharmaCeutics International Inc was incorporated under the Canada Business Corporations Act by certificate and articles of arrangement dated October 22, 2009. The Company a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs. The patented Hypermatrix technology is a multidimensional controlled-release drug delivery platform that can be applied to the efficient development of a wide range of existing and new pharmaceuticals. Based on this technology platform, it has developed several drug delivery systems and a pipeline of products and product candidates in various stages of development, including ANDAs filed with the FDA in therapeutic areas that include neurology, cardiovascular, gastrointestinal tract (GIT), diabetes and pain. The Hypermatrix technologies are applied to the development of both existing and new pharmaceuticals across a range of therapeutic classes. Its scientists have developed drug delivery technology systems, based on the Hypermatrix platform, that facilitate controlled-release delivery of a wide range of pharmaceuticals. These systems include several core technologies, which enable them to flexibly respond to a wide range of drug attributes and patient requirements, producing a desired controlled-release effect. The platform of Hypermatrix drug delivery technologies include, but are not limited to, IntelliFoam, IntelliGITransporter, IntelliMatrix, IntelliOsmotics, IntelliPaste, IntelliPellets, IntelliShuttle and nPODDDS. The Company's competitors include medical technology, pharmaceutical, biotechnology and other companies, universities and research institutions. The sales of its products by its licensees outside the United States and Canada will be subject to regulatory requirements governing the testing, registration and marketing of pharmaceuticals, which vary widely from country to country.

Ratios

vs
industry
vs
history
Forward P/E 34.97
IPCI's Forward P/E is ranked lower than
83% of the 75 Companies
in the Global Biotechnology industry.

( Industry Median: 19.72 vs. IPCI: 34.97 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 55.28
IPCI's P/B is ranked lower than
98% of the 1106 Companies
in the Global Biotechnology industry.

( Industry Median: 3.65 vs. IPCI: 55.28 )
Ranked among companies with meaningful P/B only.
IPCI' s P/B Range Over the Past 10 Years
Min: 6.86  Med: 15.28 Max: 551.11
Current: 55.28
6.86
551.11
P/S 26.93
IPCI's P/S is ranked lower than
66% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: 12.50 vs. IPCI: 26.93 )
Ranked among companies with meaningful P/S only.
IPCI' s P/S Range Over the Past 10 Years
Min: 6  Med: 22.54 Max: 4290
Current: 26.93
6
4290
Current Ratio 1.36
IPCI's Current Ratio is ranked lower than
82% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. IPCI: 1.36 )
Ranked among companies with meaningful Current Ratio only.
IPCI' s Current Ratio Range Over the Past 10 Years
Min: 0.42  Med: 3.12 Max: 23.75
Current: 1.36
0.42
23.75
Quick Ratio 1.36
IPCI's Quick Ratio is ranked lower than
78% of the 948 Companies
in the Global Biotechnology industry.

( Industry Median: 3.91 vs. IPCI: 1.36 )
Ranked among companies with meaningful Quick Ratio only.
IPCI' s Quick Ratio Range Over the Past 10 Years
Min: 0.42  Med: 3.02 Max: 23.75
Current: 1.36
0.42
23.75
Days Sales Outstanding 77.46
IPCI's Days Sales Outstanding is ranked lower than
61% of the 592 Companies
in the Global Biotechnology industry.

( Industry Median: 62.87 vs. IPCI: 77.46 )
Ranked among companies with meaningful Days Sales Outstanding only.
IPCI' s Days Sales Outstanding Range Over the Past 10 Years
Min: 0.5  Med: 42.08 Max: 352.81
Current: 77.46
0.5
352.81

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -7.60
IPCI's 3-Year Average Share Buyback Ratio is ranked higher than
60% of the 556 Companies
in the Global Biotechnology industry.

( Industry Median: -10.90 vs. IPCI: -7.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
IPCI' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -120.7  Med: -19.9 Max: -7.6
Current: -7.6
-120.7
-7.6

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 47.40
IPCI's Price/Tangible Book is ranked lower than
98% of the 1015 Companies
in the Global Biotechnology industry.

( Industry Median: 4.36 vs. IPCI: 47.40 )
Ranked among companies with meaningful Price/Tangible Book only.
IPCI' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.02  Med: 0.53 Max: 286.67
Current: 47.4
0.02
286.67
Price/Median PS Value 1.20
IPCI's Price/Median PS Value is ranked lower than
68% of the 765 Companies
in the Global Biotechnology industry.

( Industry Median: 0.97 vs. IPCI: 1.20 )
Ranked among companies with meaningful Price/Median PS Value only.
IPCI' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.35  Med: 1.83 Max: 230.88
Current: 1.2
0.35
230.88
Earnings Yield (Greenblatt) (%) -14.79
IPCI's Earnings Yield (Greenblatt) (%) is ranked lower than
61% of the 1203 Companies
in the Global Biotechnology industry.

( Industry Median: -9.03 vs. IPCI: -14.79 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
IPCI' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -671.7  Med: 0 Max: 0
Current: -14.79
-671.7
0

More Statistics

Revenue (TTM) (Mil) $2.25
EPS (TTM) $ -0.38
Beta0.92
Short Percentage of Float6.17%
52-Week Range $1.41 - 3.35
Shares Outstanding (Mil)29.79

Analyst Estimate

Nov17 Nov18 Nov19
Revenue (Mil $) 21 34 104
EPS ($) 0.07 0.27 1.67
EPS w/o NRI ($) 0.07 0.27 1.67
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for IPCI

Headlines

Articles On GuruFocus.com
Analysts are Bullish on IntelliPharmaceuticals Following Deal with Teva Pharmaceuticals Feb 04 2015 

More From Other Websites
Intellipharmaceutics Announces 2016 Year End Results Feb 10 2017
Intellipharmaceutics Painkiller Qualifies for FDA Review Feb 03 2017
Intellipharmaceutics Announces FDA Acceptance for Filing of NDA for Rexista™ (oxycodone... Feb 02 2017
Intellipharmaceutics Reports on Launch of Additional Strengths of Generic Focalin XR® by Par... Jan 06 2017
Intellipharmaceutics Reports on Launch of Additional Strengths of Generic Focalin XR® by Par... Jan 06 2017
Intellipharmaceutics to Present at the Biotech Showcase™ Dec 29 2016
Intellipharmaceutics to Present at the Biotech Showcase™ Dec 29 2016
Intellipharmaceutics Announces Issuance of U.S. and Canadian Patents Covering Aspects of its... Dec 21 2016
Intellipharmaceutics Announces Issuance of U.S. and Canadian Patents Covering Aspects of its... Dec 21 2016
Intellipharmaceutics to Present at the LD Micro Main Event Nov 29 2016
IntelliPharmaCeutics Intl Inc (USA) (IPCI) Needs A Partner Nov 28 2016
Intellipharmaceutics Submits NDA for Pain Treatment Rexista Nov 28 2016
IntelliPharmaCeutics (IPCI) Jumps: Stock Adds 5% in Session Nov 28 2016
The FDA's Historic Caution On Abuse Deterrent Labeling Nov 25 2016
Intellipharmaceutics Submits New Drug Application for Rexista® (oxycodone hydrochloride extended... Nov 25 2016
Raging Bull Portfolio: Abeona Therapeutics Inc (ABEO) And IntelliPharmaCeutics Intl Inc (USA) (IPCI) Nov 07 2016
Will IntelliPharmaCeutics (IPCI) Continue to Surge Higher? Oct 20 2016
Intellipharmaceutics to Present at Dawson James Securities Growth Stock Conference Oct 14 2016
Intellipharmaceutics Announces Third Quarter 2016 Results Oct 13 2016
IntelliPharmaCeutics (IPCI) Jumps: Stock Moves 5.4% Higher Oct 13 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK